Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial

BACKGROUND: Sentinel lymph node biopsy is standard for staging clinically node-negative (cN0) breast cancer, but the dual tracer gold-standard radioisotope-blue dye technique is unavailable in resource-limited settings. Fluorescein, an inexpensive, safe, visible-light tracer, has no randomized data after neoadjuvant chemotherapy (NACT). We compared fluorescein-methylene blue with methylene blue alone for sentinel lymph node biopsy in post-NACT cN0 patients and, secondarily, assessed the accuracy of axillary ultrasound. METHODS: In this randomized pilot feasibility trial, post-NACT cN0 breast cancer patients were randomized 1:1 to fluorescein-methylene blue (FlaB) or methylene blue alone after dye allergy testing. All patients underwent completion axillary lymph node dissection as the reference standard. Identification rate and false-negative rate were estimated with 95% confidence intervals. RESULTS: Of 136 patients who received NACT, 62 (45.6%) had a clinical complete nodal response and were recruited; 2 (3.2%) were excluded for methylene blue allergy, leaving 30 randomized per group, with all 60 completing the protocol. IR: 93.3% (28/30; 95% CI, 78.7-98.1) with FlaB versus 83.3% (25/30; 95% CI, 66.4-92.7) with methylene blue alone (difference, 10.0 percentage points; p = 0.23). FNR: 11.1% (2/18; 95% CI, 3.1-32.8) versus 12.5% (2/16; 95% CI, 3.5-36.0; p = 0.87). On secondary analysis, axillary ultrasound was normal in 30 of 62 patients (48.4%) and suspicious in 32 (51.6%); against final pathology, its sensitivity was 80.6%, and its negative predictive value was 76.7%; 7 of the 36 node-positive patients (19.4%) had a sonographically normal axilla. No dye-related adverse events occurred. CONCLUSION: FlaB achieved an identification rate above the 90% benchmark and a false-negative rate comparable to radioisotope-based dual-tracer series. Axillary ultrasound did not reliably exclude residual nodal disease (negative predictive value 76.7%) and cannot replace pathological nodal staging after NACT. Fluorescein-methylene blue is a safe, radioisotope-free dual-tracer strategy for SLNB in resource-limited settings.

Authors

Institutions

Publication Details

Journal
World Journal of Surgery
Published
2026-11-16
DOI
https://doi.org/10.1002/wjs.70696
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial

Dharma Ram Poonia, Sanjeev Misra, Rahul Yadav, Puneet Pareek et al.
World Journal of Surgery
Breast Cancer Treatment Studies
article

Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial

Dharma Ram Poonia, Sanjeev Misra, Rahul Yadav, Puneet Pareek, Byshetty Rajendar, Jeewan Ram Vishnoi, Poonam Abhay Elhence, Nivedita Sharma, Taruna Yadav
article en

Abstract

BACKGROUND: Sentinel lymph node biopsy is standard for staging clinically node-negative (cN0) breast cancer, but the dual tracer gold-standard radioisotope-blue dye technique is unavailable in resource-limited settings. Fluorescein, an inexpensive, safe, visible-light tracer, has no randomized data after neoadjuvant chemotherapy (NACT). We compared fluorescein-methylene blue with methylene blue alone for sentinel lymph node biopsy in post-NACT cN0 patients and, secondarily, assessed the accuracy of axillary ultrasound. METHODS: In this randomized pilot feasibility trial, post-NACT cN0 breast cancer patients were randomized 1:1 to fluorescein-methylene blue (FlaB) or methylene blue alone after dye allergy testing. All patients underwent completion axillary lymph node dissection as the reference standard. Identification rate and false-negative rate were estimated with 95% confidence intervals. RESULTS: Of 136 patients who received NACT, 62 (45.6%) had a clinical complete nodal response and were recruited; 2 (3.2%) were excluded for methylene blue allergy, leaving 30 randomized per group, with all 60 completing the protocol. IR: 93.3% (28/30; 95% CI, 78.7-98.1) with FlaB versus 83.3% (25/30; 95% CI, 66.4-92.7) with methylene blue alone (difference, 10.0 percentage points; p = 0.23). FNR: 11.1% (2/18; 95% CI, 3.1-32.8) versus 12.5% (2/16; 95% CI, 3.5-36.0; p = 0.87). On secondary analysis, axillary ultrasound was normal in 30 of 62 patients (48.4%) and suspicious in 32 (51.6%); against final pathology, its sensitivity was 80.6%, and its negative predictive value was 76.7%; 7 of the 36 node-positive patients (19.4%) had a sonographically normal axilla. No dye-related adverse events occurred. CONCLUSION: FlaB achieved an identification rate above the 90% benchmark and a false-negative rate comparable to radioisotope-based dual-tracer series. Axillary ultrasound did not reliably exclude residual nodal disease (negative predictive value 76.7%) and cannot replace pathological nodal staging after NACT. Fluorescein-methylene blue is a safe, radioisotope-free dual-tracer strategy for SLNB in resource-limited settings.

World Journal of Surgery
All India Institute of Medical Sciences Jodhpur (IN), CARE Hospitals (IN), King George's Medical University (IN)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon